238 related articles for article (PubMed ID: 14705201)
1. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph.
Rodríguez-Hornedo N; Murphy D
J Pharm Sci; 2004 Feb; 93(2):449-60. PubMed ID: 14705201
[TBL] [Abstract][Full Text] [Related]
2. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder.
Murphy D; Rodríguez-Cintrón F; Langevin B; Kelly RC; Rodríguez-Hornedo N
Int J Pharm; 2002 Oct; 246(1-2):121-34. PubMed ID: 12270615
[TBL] [Abstract][Full Text] [Related]
3. Towards a universal dissolution medium for carbamazepine.
El-Massik MA; Abdallah OY; Galal S; Daabis NA
Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
[TBL] [Abstract][Full Text] [Related]
4. Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid.
Lehto P; Aaltonen J; Tenho M; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
J Pharm Sci; 2009 Mar; 98(3):985-96. PubMed ID: 18661533
[TBL] [Abstract][Full Text] [Related]
5. Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate.
Crison JR; Weiner ND; Amidon GL
J Pharm Sci; 1997 Mar; 86(3):384-8. PubMed ID: 9050810
[TBL] [Abstract][Full Text] [Related]
6. Investigation of intrinsic dissolution behavior of different carbamazepine samples.
Sehić S; Betz G; Hadzidedić S; El-Arini SK; Leuenberger H
Int J Pharm; 2010 Feb; 386(1-2):77-90. PubMed ID: 19900519
[TBL] [Abstract][Full Text] [Related]
7. Crystallization of carbamazepine pseudopolymorphs from nonionic microemulsions.
Kogan A; Popov I; Uvarov V; Cohen S; Aserin A; Garti N
Langmuir; 2008 Feb; 24(3):722-33. PubMed ID: 18163657
[TBL] [Abstract][Full Text] [Related]
8. Influence of Simulated Gastrointestinal Fluids on Polymorphic Behavior of Anhydrous Carbamazepine Form III and Biopharmaceutical Relevance.
Bhise SB; Rajkumar M
PDA J Pharm Sci Technol; 2010; 64(1):28-36. PubMed ID: 21502001
[TBL] [Abstract][Full Text] [Related]
9. The effect of egg albumin on the crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets and in aqueous solutions.
Katzhendler I; Azoury R; Friedman M
J Control Release; 2000 Apr; 65(3):331-43. PubMed ID: 10699292
[TBL] [Abstract][Full Text] [Related]
10. To evaluate the effect of addition of an anionic surfactant on solid dispersion using model drug indomethacin.
Dave RH; Patel AD; Donahue E; Patel HH
Drug Dev Ind Pharm; 2012 Aug; 38(8):930-9. PubMed ID: 22085470
[TBL] [Abstract][Full Text] [Related]
11. Initial dissolution kinetics of cocrystal of carbamazepine with nicotinamide.
Hattori Y; Sato M; Otsuka M
J Pharm Pharmacol; 2015 Nov; 67(11):1512-8. PubMed ID: 26285918
[TBL] [Abstract][Full Text] [Related]
12. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
Miller JM; Beig A; Krieg BJ; Carr RA; Borchardt TB; Amidon GE; Amidon GL; Dahan A
Mol Pharm; 2011 Oct; 8(5):1848-56. PubMed ID: 21800883
[TBL] [Abstract][Full Text] [Related]
13. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: a single crystal study using SEM and Raman microscopy.
Tian F; Sandler N; Gordon KC; McGoverin CM; Reay A; Strachan CJ; Saville DJ; Rades T
Eur J Pharm Biopharm; 2006 Nov; 64(3):326-35. PubMed ID: 16846721
[TBL] [Abstract][Full Text] [Related]
14. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.
Omori M; Watanabe T; Uekusa T; Oki J; Inoue D; Sugano K
Mol Pharm; 2020 Oct; 17(10):3825-3836. PubMed ID: 32870691
[TBL] [Abstract][Full Text] [Related]
15. Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.
Yamashita H; Sun CC
Pharm Res; 2017 Dec; 35(1):4. PubMed ID: 29288433
[TBL] [Abstract][Full Text] [Related]
16. In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour.
Qiao N; Wang K; Schlindwein W; Davies A; Li M
Eur J Pharm Biopharm; 2013 Apr; 83(3):415-26. PubMed ID: 23159709
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic study of griseofulvin dissolution into surfactant solutions under laminar flow conditions.
Rao VM; Lin M; Larive CK; Southard MZ
J Pharm Sci; 1997 Oct; 86(10):1132-7. PubMed ID: 9344170
[TBL] [Abstract][Full Text] [Related]
18. Effects of Polymer/Surfactant as Carriers on the Solubility and Dissolution of Fenofibrate Solid Dispersion.
Yang B; Wu L; Ke J; Zhou L; Chen M; Li S; Feng X
AAPS PharmSciTech; 2019 Feb; 20(3):102. PubMed ID: 30723877
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.
Rahman Z; Samy R; Sayeed VA; Khan MA
Pharm Dev Technol; 2012; 17(4):457-65. PubMed ID: 21265708
[TBL] [Abstract][Full Text] [Related]
20. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.
Lehto P; Kortejärvi H; Liimatainen A; Ojala K; Kangas H; Hirvonen J; Tanninen VP; Peltonen L
Eur J Pharm Biopharm; 2011 Aug; 78(3):531-8. PubMed ID: 21329757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
